RZLT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States...

Stats
Dagens volum	335 692
Gjennomsnittsvolum	342 610
Markedsverdi	132.82M
EPS	$0 ( 2024-02-09 )
Neste inntjeningsdato	( $-0.340 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.01
ATR14	$0.0220 (0.66%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Roberts Brian Kenneth	Buy	500	Common Shares
2022-07-22	Handok, Inc.	Buy	3 157 895	Common Shares
2021-10-15	Handok, Inc.	Buy	769 231	Common Shares
2024-03-15	Evans Daron	Buy	20 000	Common Shares
2024-03-14	Roberts Brian Kenneth	Buy	10 000	Common Shares

INSIDER POWER
100.00
Last 96 transactions
Buy: 107 305 216 \| Sell: 58 571 575

Volum Korrelasjon

Lang: -0.14 (neutral)

Kort: -0.03 (neutral)

Signal:(52.49) Neutral

Rezolute, Inc. Korrelasjon

10 Mest positive korrelasjoner
XBIT	0.97
MTEK	0.968
VNOM	0.967
FANG	0.963
ENTX	0.961
PRIM	0.958
APP	0.954
SVFAU	0.954
IXAQ	0.951
AEAC	0.951

10 Mest negative korrelasjoner
HCDIP	-0.96
AKTX	-0.959
HAIN	-0.95
EMBC	-0.947
SPTN	-0.94
SHEN	-0.939
XPON	-0.936
UONEK	-0.934
PEAR	-0.934
BPTH	-0.933

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Rezolute, Inc. Korrelasjon - Valuta/Råvare

-0.13
( neutral )

-0.15
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.35
( neutral )

0.18
( neutral )

Rezolute, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2023
Omsetning:	$0
Bruttogevinst:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2022
Omsetning:	$0
Bruttogevinst:	$-256 000 (0.00 %)
EPS:	$-2.13

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.72

Financial Reports:

No articles found.

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Sanntidsoppdatering for Rezolute, Inc. [RZLT]

Upcoming Earnings Alert